Clinical Trials Directory

Trials / Conditions / Poorly Differentiated Thyroid Gland Carcinoma

Poorly Differentiated Thyroid Gland Carcinoma

12 registered clinical trials studyying Poorly Differentiated Thyroid Gland Carcinoma.

StatusTrialSponsorPhase
Active Not RecruitingLenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Met
NCT04171622
M.D. Anderson Cancer CenterPhase 2
Active Not RecruitingSelpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
NCT04759911
M.D. Anderson Cancer CenterPhase 2
WithdrawnPembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
NCT04731740
Saint Petersburg State University, RussiaPhase 2
Active Not RecruitingPDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
NCT04544111
Memorial Sloan Kettering Cancer CenterPhase 2
Active Not RecruitingTesting the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated T
NCT03914300
National Cancer Institute (NCI)Phase 2
TerminatedAdaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
NCT03630120
H. Lee Moffitt Cancer Center and Research InstitutePhase 2
Active Not RecruitingLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Ca
NCT03449108
M.D. Anderson Cancer CenterPhase 2
CompletedLenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
NCT02973997
Academic and Community Cancer Research UnitedPhase 2
Active Not RecruitingAtezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
NCT03181100
M.D. Anderson Cancer CenterPhase 2
CompletedIodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
NCT02393690
Academic and Community Cancer Research UnitedPhase 2
Active Not RecruitingTrametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
NCT02152995
National Cancer Institute (NCI)Phase 2
CompletedCabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
NCT01811212
National Cancer Institute (NCI)Phase 2